Immatics is a biopharmaceutical company developing TCR-based immunotherapies using its proprietary ImmTAX platform to target cancer and other serious diseases. The company's lead product, KIMMTRAK, a soluble bispecific TCR approved by the FDA, treats uveal melanoma and generates commercial revenue through sales to healthcare providers; the company also maintains a pipeline of additional product candidates in clinical development. Revenue depends on successful regulatory approvals for new candidates, market adoption by physicians and patients, and reimbursement decisions by government and private payors, with the company's prospects tied to its ability to advance clinical programs, secure regulatory approval, and maintain patent protection in a highly regulated and competitive biotechnology industry.